Serum HDAC3 as an Early Indicator for Predicting and Staging Acute Kidney Injury Associated with Sepsis: A Prospective Cohort Analysis - Report - MDSpire
Advertisement
Serum HDAC3 as an Early Indicator for Predicting and Staging Acute Kidney Injury Associated with Sepsis: A Prospective Cohort Analysis
Clinical Report: Serum HDAC3 as an Early Indicator for Predicting AKI
Overview
This study investigates serum HDAC3 levels as a potential early biomarker for predicting and staging acute kidney injury (AKI) associated with sepsis. Findings suggest that elevated serum HDAC3 may indicate the onset of sepsis-associated AKI within seven days, highlighting its potential clinical utility.
Background
Sepsis is a critical condition that can lead to severe organ dysfunction, including acute kidney injury (AKI), which affects over 40% of septic patients and has a high mortality rate. Traditional markers for AKI, such as serum creatinine, often fail to provide timely diagnosis, necessitating the search for more sensitive biomarkers. Identifying early indicators of AKI can significantly improve patient outcomes in sepsis management.
Data Highlights
No numerical data provided in the source material.
Key Findings
Over 40% of patients with sepsis develop AKI, with mortality rates ranging from 50% to 70%.
Current AKI diagnosis relies on serum creatinine and urine output, which may not detect early renal injury.
Serum HDAC3 levels were measured in patients without SA-AKI to evaluate its predictive capacity.
HDAC3 is implicated in renal injury and may serve as a diagnostic marker for SA-AKI.
Prior studies indicate that selective HDAC3 inhibition can reduce renal injury in experimental models.
Clinical Implications
The identification of serum HDAC3 as a potential biomarker for early detection of SA-AKI could enhance clinical decision-making and patient management in septic patients. Early intervention based on HDAC3 levels may improve outcomes and reduce the progression of kidney injury.
Conclusion
Serum HDAC3 shows promise as an early biomarker for predicting and staging AKI in sepsis, warranting further investigation to validate its clinical utility.
